Anika Therapeutics | ANIK - Des Atouts





Des Atouts Changement Date
Abbott USD 110.43B 23.72B 2026-03
Agenus USD 186.46M 40.34M 2026-03
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Integra LifeSciences USD 3.58B 24.28M 2026-03
Intrexon USD 73.16M 77.88M 2024-06
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Merit Medical Systems USD 2.72B 33.36M 2026-03
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Smith & Nephew USD 10.69B 150M 2025-12
Stryker USD 46.29B 1.55B 2026-03
Veracyte USD 1.44B 30.38M 2026-03
Xencor USD 736.85M 138.65M 2026-03
Zimmer Biomet Holdings USD 22.72B 370.1M 2026-03